138 results about "Endometrioses" patented technology

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

This invention relates to the field of medical information management technology, including an AI-based endometriosis management system. The system comprises a thickness dynamic monitoring module, an inflammation level assessment module, a lesion spread analysis module, a periodic lesion tracking module, and a disease progression analysis module. In this invention, AI is used to segment ultrasound image data, enabling dynamic monitoring of lesion areas. Lesion boundaries are extracted, and changes in local inflammatory marker concentrations are calculated, making the screening of abnormal inflammatory areas more accurate and enabling early identification of lesion development. The tracking of periodic lesions, combined with analysis of lesion contour changes and area increases / decreases, enhances the quantitative control of disease progression. The future development trend of lesions, combined with the calculation of periodic inflammatory pathways, makes the prediction of disease evolution more consistent with physiological changes. Multi-dimensional lesion analysis combined with AI intelligent calculation expands the diagnosis and treatment of endometriosis from static assessment to dynamic trend prediction, improving the adaptability of personalized treatment plans.

The present invention relates to a non-invasive test for the detection of deep endometriosis. Particularly, although not exclusively, aspects of the present invention relate to one or more glycolysis-associated biomarkers (e.g., phosphoglycerate mutase 1 (PGAM1), Enolase-1 (ENO1), phosphofructokinase-1 (PFKP) and / or Hexokinase) and / or cytokines associated with aerobic glycolysis (e.g., IL-6 and / or TGF-β) which can be used to determine the likelihood of a subject having deep endometriosis based on a sample obtained from the subject.

A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from the list consisting of: hemoglobin subunit beta and inter-alpha-trypsin inhibitor light chain, in a sample from a subject, and (b) using the expression level to determine whether the subject has endometriosis.

The present invention relates to a composition comprising eptinezumab and LuAG09222. This composition may be used, for example, to treat or prevent headache, pain, migraine, cluster headache, or endometriosis.

The present invention relates to a conjugate comprising a FAP targeting ligand and an effector for use in the treatment and / or diagnosis of endometriosis, as well as associated methods and kits.

The present invention relates to an integrated diagnostic system for deep endometriosis and / or adenomyosis, comprising three interconnected platforms and a method for analysing images generated by algorithms. The first platform combines patient medical history data with transvaginal ultrasound and / or pelvic magnetic resonance images, using algorithms to generate clear and detailed images of lesions. The method for analysing these images includes pre-processing, merging of clinical data and images, lesion identification, and comparison with a clinical database, resulting in a visual and descriptive analysis of the lesions, facilitating early and assertive diagnosis. The second platform is a communication network among specialist physicians, who perform a second reading of the images and issue a validated final report. The third platform is educational, offering personalised training and mentoring for imaging physicians using the images generated by the first platform to improve their diagnostic skills. The system reduces diagnostic time, increases accuracy, and contributes to the continuous professional development of physicians involved in the management of deep endometriosis and / or adenomyosis.

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

The application discloses a traditional Chinese medicine formula for treating endometriosis, which comprises the following components in the weight fractions: cassia twig 14-16 parts, five spirit fat 8-12 parts, raw safflower 4-8 parts, xiaosha 4-8 parts, blood 4-8 parts, leech 2-5 parts, white peony root 8-12 parts, ophiopogon 8-12 parts, uncaria 12-14 parts, amber 4-8 parts and licorice 4-8 parts. The application is innovatively combined with the combination of heart calming and liver regulating on the basis of the original Pingchongjiangni formula, that is, warming heart yang to calm the rushing qi, calming heart qi to lower the rushing qi, and calming liver qi to follow the rushing qi, so that the purpose of calming the rushing qi is achieved. The traditional Chinese medicine formula can not only effectively relieve the dysmenorrhea of the patients with endometriosis, but also improve the psychological state such as depression and anxiety, and still has certain curative effect after stopping the medicine for three months.

Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a —COOH group or a —OH group; R3′ and R3″ represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; R4 and R5 represent a hydrogen atom, a halogen atom, a —IMH2 group, a (C1-C3)alkyl group, a (C1-C3)alkoxy group, or a —OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a ═NOCH3 group or a (C3-C5)cycloalkyl group; R7 represents a hydrogen atom, a methyl group, a —OH group or a fluorine atom; R6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 3 to 8 membered-heterocycloalkyl group, a (C1-C6)alkyl group or a phenyl (C1-C2) alkyl group; X represents —CH2—, —O— or —S—; Y represents —CH═, —N═ or —CR″═; R8 represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; R9 represents a hydrogen atom or a fluorine atom; RIO and RIO′ represent a hydrogen atom or a fluorine atom; R11 represents a hydrogen atom a (C1-C3)alkyl group or a cyclopropyl group; n is 0, 1 or 2, and m is 0 or 1. Further disclosed are process for preparing the same, pharmaceutical compositions comprising them as well as said compounds of formula (I) for use as an inhibitor and degrader of estrogen receptors, in particular in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

The invention belongs to the technical field of bioengineering, and provides a drug-loaded targeted nano platform for targeted delivery of ZIF-8 drug-loaded nanoparticles by macrophages, a preparation method and an application, aiming at the technical problem that complications are easily caused by the existing treatment means of endometriosis, so that the invention provides a drug-loaded targeted nano platform for targeted delivery of ZIF-8 drug-loaded nanoparticles by macrophages, and a preparation method and application of the drug-loaded targeted nano platform. According to the invention, the ZIF-8 nano-particles and the drugs aiming at the energy metabolism level are combined to be used as the carrier, so that endometriosis cells with acidic cell microenvironment can be targeted, drug controlled release can be realized in the acidic environment of lesions, and the effective uptake of the endometriosis cells to the drugs is enhanced, thereby effectively increasing the uptake rate and the drug concentration at the target position, and improving the curative effect of the drug on the endometriosis cells. Meanwhile, the distribution of the medicine in normal tissues or cells is reduced, and the toxic and side effects of the medicine are reduced; and through the design of combining the macrophages with the ZIF-8 nano-particle carrier, the drug targeting property of the ZIF-8 nano-particle carrier can be obviously improved.

The invention provides a nucleic acid aptamer specifically combined with endometriosis cells and application of the nucleic acid aptamer, and belongs to the technical field of biology. The nucleic acid aptamer capable of being specifically combined with the endometriosis cells is screened out through the Cell-SELEX technology with living cells as screening objects, and the nucleic acid aptamer has the advantages of being high in specificity, high in affinity, high in specificity, high in specificity and high in specificity. The probe can be used for early diagnosis of endometriosis, tissue biopsy, ectopic endometrial tissue excision guided by fluorescence, targeted drug development and the like.

The present invention relates to levonorgestrel for use in a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 µg / day to about 100 µg / day. The invention further relates to levonorgestrel for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea comprising continuously administering about 60 µg / day to about 160 µg / day of levonorgestrel. Delivery devices, preferably, intravaginal rings for putting the methods in practice are also envisaged.

The invention discloses a system for endometriosis diagnosis and a computer storage medium. Aiming at major adjustment of endometriosis diagnosis standards, biomarkers and ploidy information of circulating endometrial cells in easily available samples such as peripheral blood of a patient are detected, and comprehensive risk assessment is performed by utilizing an optimization algorithm model, so that the diagnosis accuracy of endometriosis is improved. The invention provides an objective and quantifiable noninvasive diagnostic tool adapted to the adjusted standard, and the method solves the problem of missed diagnosis caused by false negative in the existing surgical diagnostic method, and has important clinical application value, social benefit and market prospect for improving the overall diagnostic level of endometriosis.

The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising these compounds. The compounds provided herein can be used as prostaglandin E2 (PGE2) EP4 receptor antagonists, which makes them very useful for therapy, particularly for the treatment or prevention of cancer, neovascular eye disease, inflammatory pain or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or endometriosis. #imgabs0#

The present invention relates to methods of treating endometriosis or preventing recurrence of endometriosis. In particular, the present invention relates to a method of treating endometriosis and relapse thereof, comprising administering to a woman suffering from endometriosis a pharmaceutical composition comprising an S-alkyl isothiourea derivative, in particular S-ethyl isothiourea diethyl phosphate. The methods and pharmaceutical compositions of the present invention can retain fertility and can be fertilized.

This specification provides peptides that bind to β-catenin and compositions comprising such peptides. Agents utilizing peptides that directly bind to β-catenin can be used for imaging, diagnosis, and treatment of diseases caused by β-catenin dysfunction. This specification also provides methods for using such peptides and compositions in imaging, diagnosis, and treatment of tissue-invasive diseases, including endometriosis.

The present disclosure relates, in part, to the selective inhibition of JUN N-terminal kinase (JNK1, JNK2, and / or JNK3; the present invention relates to compounds of formulae (I) and (II), which are also known as MAPK8, MAPK9 and / or MAPK10), pharmaceutical compositions thereof and methods of their use for treating, preventing and / or ameliorating one or more diseases and / or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and / or type 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting a disease and / or disorder in a subject with a suitable diagnostic method.

A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from Table 1, 2 or 3 in a sample from a subject, where in the at least one protein may be selected from the list comprising: Beta-Ala-His dipeptidase, Apolipoprotein L1, Methanethiol oxidase, Vitamin K-dependent protein S, von Willebrand factor, Plasminogen, Selenoprotein P, Protein disulfide-isomerase A6 and Inter-alpha-trypsin inhibitor heavy chain H3, and (b) using the expression level to determine whether the subject has endometriosis.

Disclosed are compositions useful in the treatment or prevention of endometriosis and pain. Also disclosed are methods for the treatment and / or prevention of endometriosis and pain.

The present invention relates to a method for diagnosing, predicting disease development, disease progression and / or disease outcome, predicting sensitivity to treatment and / or classifying in the context of female genital tract diseases or conditions, in particular endometriosis, in which biomarkers in Table 1, e.g., CCL5 and / or NEAT1, are determined. The invention further relates to a pharmaceutical product for a patient stratified according to the method of the invention and to a composition comprising an agent for detecting a biomarker in Table 1 for diagnosing a female genital tract disease or condition.

The invention discloses an application of miR-2355-3p in endometriosis. The research discovers that the RNA transcriptional level of miR-2355-3p in an ectopic endometrial tissue sample is obviously reduced for the first time; the mimics RNA overexpressed by miR-2355-3p is cloned to a lentiviral vector, lentiviral packaging is carried out, the miR-2355-3p mimic lentivirus is obtained, then the miR-2355-3p mimic lentivirus is used for transfecting ectopic endometrial interstitial cells, proliferation of the ectopic endometrial interstitial cells can be inhibited, apoptosis of the ectopic endometrial interstitial cells can be promoted, growth of ectopic endometrial tissues is inhibited, and the mimic RNA-mimic lentivirus can be used for treating the endometrial interstitial cells. And a new possibility is provided for developing the medicine for treating the endometriosis.

Endometriosis is a chronic oestrogen-dependent inflammatory disease characterised by the presence of endometrial tissue outside the uterine cavity. There is currently no cure for endometriosis. Here, the Inventors demonstrated in vivo that targeting CD73 significantly alters the development of endometriosis. These results thus demonstrate the relevance of CD73 as a therapeutic target in endometriosis.

The invention discloses a novel high-brightness near-infrared two-region semiconductor polymer and application thereof in preparation of an endometriosis focus near-infrared two-region imaging guided operation diagnosis and treatment reagent, and relates to the technical field of medicinal chemistry. The novel high-brightness near-infrared two-region semiconductor polymer P-BPTI provided by the invention has excellent optical performance, can absorb 808nm laser and emit near-infrared two-region light, passively targets an endometriosis site through an EPR effect, and is high in penetration depth and high in quantum yield. The nanoparticles based on the polymer can passively target a plurality of focuses in the abdominal cavity of a mouse through an EPR effect, the focuses can be effectively removed, inflammation is reduced, the cytotoxicity is low, and reliable technical support is provided for clinical diagnosis, treatment and transformation of endometriosis.

Methods for treating and non-invasively detecting endometriosis using menstrual discharge are provided.

The present application relates to bifunctional compounds of general formula I-3 'which act as degrading agents for estrogen receptor alpha (ER alpha) and are useful in the treatment of conditions associated with ER alpha-mediated transcriptional regulation, such as endometriosis and cancer. In one embodiment, the compounds are bifunctional molecules comprising a cerebron binding moiety LBM attached to a ligand ERBM that binds to ERa and comprises a benzo-fused, partially saturated 6-membered carbocyclic or heterocyclic ring. [I-3 '] wherein ERBM is selected from # imgabs0 #

The invention relates to the field of medical data processing, and discloses an endometriosis pain emotion pressure data management system based on AI prediction, which comprises a mobile terminal, an Internet of Things treatment monitoring device, an expiration detection device and a data processing server. The expiration detection device is used for detecting volatile organic compounds in expired gas by utilizing a sensor array; the Internet of Things treatment monitoring device collects heartbeat interval and skin conductivity data and executes transcutaneous nerve electrical stimulation; and the server runs the deep learning model. According to the invention, time alignment and feature splicing are carried out on physiological, expiration and behavior data through a multi-source heterogeneous data fusion module, and the pain occurrence probability is predicted by using a long-short-term memory network and an attention mechanism; early warning is generated according to the prediction result, the electrical stimulation frequency and waveform are adjusted in a closed-loop mode based on the real-time skin conductivity change slope, and multi-dimensional objective monitoring, pain risk active prediction and self-adaptive closed-loop intervention of endometriosis are achieved.

The application relates to an endometriosis subtype identification method and system, relates to the fields of bioinformatics and medical diagnosis auxiliary technologies, and takes transcriptome expression data as input, constructs a standardized expression matrix, and adopts consistency clustering to perform subtype modeling to obtain a molecular subtype label; expression timing structure of a menstrual cycle phase is introduced to perform dynamic gene identification and discriminant power evaluation, and immune cell infiltration inference and path activity scoring are combined to analyze differences of the subtypes in an immune and inflammation network, then gene-pathway / gene-cell correlation is calculated to form multi-dimensional typing information with mechanism orientation. Based on the above results, an interpretable typing identification model is constructed, which provides a new technical means for accurate diagnosis and target identification of endometriosis.

The invention discloses a medicine composition for treating endometriosis. The pharmaceutical composition for treating the endometriosis, disclosed by the invention, is prepared from the following raw materials: curcumin and epigallocatechin gallate co-delivery liposome and pterostilbene nano-structure liposome. The curcumin and the EGCG are prepared into the co-delivery liposome, so that the solubility of the curcumin in water can be remarkably improved; meanwhile, the co-delivery liposome can protect the two from being influenced by light, oxygen, temperature and pH value, and the chemical stability, the antioxidant activity and the drug effect of the liposome are improved. According to the pterostilbene nanostructure liposome prepared by the invention, the water solubility of pterostilbene is improved, the in-vitro drug release of the pterostilbene is promoted, the in-vivo stability of the pterostilbene is improved, the full absorption of drugs is facilitated, and the bioavailability of the pterostilbene is improved.